• Policy
• Reimb of HA eye drops will be restricted in KOR
• by Lee, Tak-Sun Sep 6, 2023 05:36am

• Company
• Hanmi’s Rolontis post sales of KRW 4.8 bil in H1
• by Chon, Seung-Hyun Sep 5, 2023 05:40am

• Policy
• Evaluating Tagrisso's primary benefit
• by Lee, Jeong-Hwan Sep 5, 2023 05:40am

• Company
• HK Inno.N releases its GERD drug K-CAB in Singapore
• by Chon, Seung-Hyun Sep 5, 2023 05:40am

• Policy
• Drug crime regulation,
• by Lee, Jeong-Hwan Sep 5, 2023 05:40am

• Policy
• Why many choline alfoscerates accepted price cuts
• by Lee, Tak-Sun Sep 5, 2023 05:39am

• Company
• Humira market biosimilar share
• by Kim, Jin-Gu Sep 4, 2023 05:04am

• Company
• Will Phesgo be listed with pricing premiums as a biobetter?
• by Eo, Yun-Ho Sep 4, 2023 05:04am

• Policy
• New GLP-1 RA stops reimb discussions in KOR
• by Lee, Tak-Sun Sep 4, 2023 05:04am

• Opinion
• [Reporter’s View] Disclose PVA results in advance as well
• by Lee, Tak-Sun Sep 4, 2023 05:04am